Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

about

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q48132142

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@en

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@nl

type

Item

label

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@en

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@nl

prefLabel

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@en

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@nl

P1476

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

@en

P2093

Amie L Fonder

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Miriam Hobbs

http://www.w3.org/2001/XMLSchema#string

Prashant Kapoor

http://www.w3.org/2001/XMLSchema#string

Preet Paul Singh

http://www.w3.org/2001/XMLSchema#string

Rahma Warsame

http://www.w3.org/2001/XMLSchema#string

Ronald S Go

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

Taxiarchis Kourelis

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

International staging system for multiple myeloma.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Improved survival in multiple myeloma and the impact of novel therapies.

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

P304

179-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24954

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29067723

http://www.w3.org/2001/XMLSchema#string